Solti Presents TOP-REAL Study Design for HER2+ Metastatic Breast Cancer

Solti presented the study design for TOP-REAL at the European ESMO AI & Digital Oncology congress.

The international academic phase II study evaluates a proactive monitoring model for patients with advanced or metastatic HER2-positive breast cancer receiving first-line treatment with trastuzumab deruxtecan combined with pertuzumab, TOP-REAL investigates whether digital monitoring can support earlier detection of toxicities.

Led from Spain by Solti in collaboration with Unicancer in France and WSG in Germany, the trial plans to include approximately 300 patients across 60 centres, according to 300 patients across 60 centres in Spain, France and Germany. The protocol incorporates electronic patient-reported outcomes, pulse oximetry, and continuous physiological data collection via smartwatches.

“We want patients not only to benefit from advances that allow better control of their disease, but also to live better during treatment,” said Dr. Cristina Saura, who serves as Head of the Breast Cancer Group at VHIO, Head of the Breast Cancer Unit at Vall d’Hebron University Hospital, a member of the Solti Board, and a principal investigator of TOP-REAL. “Ultimately, TOP-REAL was conceived with a dual ambition: to improve clinical outcomes and place patients’ quality of life at the center of care.”

Adverse events from cancer therapies can require dose modifications, treatment interruptions, or discontinuation. The trial specifically assesses interstitial lung disease and pneumonitis associated with trastuzumab deruxtecan by using daily oxygen saturation measurements and periodic exercise tests.

The trial includes patient profiles often underrepresented in pivotal clinical trials, such as selected individuals with active brain metastases or an ECOG performance status of 2. Patients aged 18 years or older with locally advanced or metastatic HER2-positive breast cancer who have not received prior chemotherapy or HER2-targeted therapy for advanced disease are eligible, Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management noted.

Press release i real investigates whether digital monitoring can support earlier detection of to
Photo: prnewswire.co.uk

“The TOP-REAL trial is contributing to the implementation of trastuzumab deruxtecan and pertuzumab in a real-world setting, a treatment with unprecedented efficacy,” said Dr. Santiago Escrivà, acting as a researcher in the Breast Cancer Group at VHIO, a Medical Oncologist at Vall d’Hebron University Hospital, and a principal investigator of TOP-REAL. “It allows us to better understand how we can make this treatment available to a broader range of patient profiles and optimize the management of potential toxicities by leveraging digital tools to maintain and improve quality of life.”

The digital health setup uses mobile applications such as CANKADO or Resilience depending on the country and site. These platforms collect patient data remotely and can generate automated clinical alerts.

“TOP-REAL offers a unique opportunity to integrate innovative, patient-centred supportive care pathways into a clinical trial providing patients with access to a new and effective treatment,” said Dr. Inês Vaz-Luis, principal investigator of TOP-REAL and medical oncologist and researcher at Gustave Roussy.”

The study plans to enroll approximately 300 patients across 60 clinical centres in Spain, France, and Germany, according to ClinicalTrials.gov data.

Patients use electronic patient-reported outcomes, a pulse oximeter for oxygen saturation, and continuous physiological data collection via smartwatches.

The monitoring model specifically evaluates potential toxicities including interstitial lung disease or pneumonitis associated with trastuzumab deruxtecan therapy.

The research is carried out through partnerships with WSG in Germany and Unicancer in France acting as academic group collaborators.